Is Nurix Therapeutics Inc (NRIX) overvalued? · rev $54.5M
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
This page asks whether Nurix Therapeutics Inc (NRIX) looks expensive on cached numbers — not a short thesis.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
NRIX currently screens at market cap $1.77B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NRIX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NRIX stock page for the full model, not this heading.
Not investment advice.